Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease-Reference-Cited by-同舟云学术

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease

Published:2013-08-20 Issue:1 Volume:28 Page:129-137
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kohlmann A,Nadarajah N,Alpermann T,Grossmann V,Schindela S,Dicker F,Roller A,Kern W,Haferlach C,Schnittger S,Haferlach T

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2013239.pdf

Reference42 articles.

1. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood 1999; 93: 1817–1824.

2. Dicker F, Haferlach C, Sundermann J, Wendland N, Weiss T, Kern W et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010; 24: 1528–1532.

3. Kohlmann A, Grossmann V, Harbich S, Dicker F, Alpermann T, Nadarajah N et al. Monitoring of minimal residual disease using next-generation deep-sequencing in 460 acute myeloid leukemia cases identifies RUNX1 mutated patients with resistant disease. Blood 2011; 118: 747a.

4. Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 2011; 117: 2348–2357.

5. Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Rock J, Paschka P et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011; 29: 1364–1372.

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study;Blood Cancer Journal;2024-06-13

2. Prognostic Role and Clinical Utility of Measurable Residual Disease in Acute Myeloid Leukemia;Advances in Oncology;2024-05

3. Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target;Aspects of Molecular Medicine;2023-12

4. Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives;Cancers;2023-04-26

5. Place des outils moléculaires dans les leucémies aiguës myéloïdes en 2023;Revue Francophone des Laboratoires;2023-04